BioSpace News Archive

High interest in R&D exercises, expansion in commonness of disease, and development in mindfulness in regards to gene therapy drive the development of the worldwide gene therapy market

Increase in R&D and usage of innovative packaging, advanced manufacturing processes to develop eco-friendly packaging solutions, and rise in product innovations drive the growth of the global Pharmaceutical Packaging Market.

ulrich medical USA, Inc., a medical device company focused on developing and commercializing musculoskeletal implant technologies in the United States, announced twenty years of success with the Small VBR vertebral body replacement system.

Visus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, announced that the company will host its first Capital Markets Day for investors, analysts, and media on August 31, 2021, from 10:00 a.m. to 2:00 p.m. ET at Convene, 530 Fifth Avenue in New York City.

The Biotechnology Institute reported on the success of its signature program, the 2021 International BioGENEius Challenge and that of its newest venture, BioDiversity 2021, both in partnership with Johnson & Johnson.

Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing, today announced the execution of a definitive agreement to acquire Solentim, a trusted global leader of solutions for the isolation and characterization of high value single cell clones in cell line development (CLD) applications.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced that it has issued inducement awards to nine non-executive employees.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced second quarter 2021 financial results and provided an operational update.

Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, or immuno-dermatology, reported financial results for the quarter ended June 30, 2021, and provided a business update.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and first six months of 2021.